Patents by Inventor Arun UNNI

Arun UNNI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
    Publication number: 20180153978
    Abstract: A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.
    Type: Application
    Filed: February 2, 2018
    Publication date: June 7, 2018
    Applicants: The Board of Regents of the University of Texas System, Yale University, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Chandrashekhar PASARE, Scott N. FURLAN, Noah W. PALM, Arun UNNI
  • TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
    Publication number: 20170007685
    Abstract: A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.
    Type: Application
    Filed: November 5, 2014
    Publication date: January 12, 2017
    Applicants: The Board of Regents of the University of Texas System, Yale University, The United States of America, as represented by th e Secretary, Department of Health and Human Servi
    Inventors: Chandrashekhar PASARE, Scott N. FURLAN, Noah W. PALM, Arun UNNI